home / stock / biib / biib articles

BIIB Articles, Biogen Inc. - From 11/09/23

Stock Information
Company Name: Biogen Inc.
Stock Symbol: BIIB
Market: NASDAQ
Website: biogen.com
Menu
BIIB BIIB Quote BIIB Short BIIB News BIIB Articles BIIB Message Board
Get BIIB Alerts

News, Short Squeeze, Breakout and More Instantly...
These Analysts Revise Their Forecasts On Biogen After Q3 Results | Benzinga

Biogen Inc (NASDAQ: BIIB) reported better-than-expected third-quarter earnings. Biogen posted quarterly sales of $2.53 billion, beating the consen...
US Stocks Set To Snap Winning Streak, Treasuries Rally, Oil Tumbles: What's Driving Markets Wednesday? | Benzinga

U.S. stocks experienced a drop as of midday trading in New York, potentially ending a prolonged streak of consecutive daily gains as investors eval...

Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides | Benzinga

Biogen Inc (NASDAQ: BIIB) posted Q3 FY23 sales of $2.53 billion, beating the consensus of $2.39 billion, up 1% Y/Y and 3% at constan...

US Stocks Set To Open Flat After Hot 7-Day Rally: Traders Sharpen Focus On Powell's Speech, Disney Earnings | Benzinga

Stock futures indicate a subdued opening on Wednesday after several consecutive gains in major averages. Traders are eagerly awaiting Federal Reser...
Biogen Appoints Monish Patolawala to its Board of Directors | Benzinga

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) today announced the appointment of Monish Patolawala, currently P...

Here's How Much You Would Have Made Owning Biogen Stock In The Last 15 Years | Benzinga

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 1.68% on an annualized basis producing an average annual return of 12.42...

Assessing Biogen's Performance Against Competitors In Biotechnology Industry | Benzinga

Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors an...
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer's Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzhe

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Pa...

Biogen Says New Data Shows Promise For Potential New Generation Of Treatments In Early Alzheimer's Disease | Benzinga

Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) t...

Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting | Benzinga

Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer's disease Additional late-...
Previous 10 Next 10